Richard Simcock
Macmillan Cancer Support(GB)University Hospitals Sussex NHS Foundation Trust(GB)Medical Research Foundation(GB)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Advances in Oncology and Radiotherapy, Head and Neck Cancer Studies, Global Cancer Incidence and Screening, HER2/EGFR in Cancer Research
Most-Cited Works
- → 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial(2019)278 cited
- → COVID-19: Global radiation oncology’s targeted response for pandemic preparedness(2020)241 cited
- → Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study(2014)171 cited
- → Beyond Performance Status(2020)109 cited
- → ARIX: A randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer(2012)104 cited
- → PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.